Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Research & Development (2021 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Research & Development for 5 consecutive years, with $3.4 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 13.74% to $3.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.2 million through Dec 2025, down 32.68% year-over-year, with the annual reading at $13.2 million for FY2025, 32.68% down from the prior year.
  • Research & Development hit $3.4 million in Q4 2025 for ARS Pharmaceuticals, up from $2.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $17.7 million in Q2 2021 to a low of -$25.4 million in Q4 2021.
  • Historically, Research & Development has averaged $4.6 million across 5 years, with a median of $4.4 million in 2022.
  • Biggest YoY gain for Research & Development was 118.57% in 2022; the steepest drop was 75.49% in 2022.
  • Year by year, Research & Development stood at -$25.4 million in 2021, then soared by 118.57% to $4.7 million in 2022, then decreased by 27.73% to $3.4 million in 2023, then dropped by 11.08% to $3.0 million in 2024, then grew by 13.74% to $3.4 million in 2025.
  • Business Quant data shows Research & Development for SPRY at $3.4 million in Q4 2025, $2.8 million in Q3 2025, and $4.0 million in Q2 2025.